Skip to main content
. 2019 Jul 26;3(15):2264–2271. doi: 10.1182/bloodadvances.2019000152

Table 2.

Efficacy summary

IWG-MRT-ECNM response*, n (%) Overall population (N = 10)
ORR (CR + PR +CI) 0 (0)
Stable disease 8 (80)
Progressive disease 1 (10)
Not evaluable 1 (10)

For the full listing and definitions of response criteria, please see the IWG-MRT-ECNM consensus guidelines.29

CI, clinical improvement